Lupin Limited (NSE: LUPIN) announced receiving tentative approval from the U.S. FDA for its Apixaban Oral Suspension 1.25mg/mL.
Glenmark Pharmaceuticals Limited (GLENMARK) receives Establishment Inspection Report from U.S. FDA for its Goa facility with Voluntary Action Indicated status.
Lupin Limited (LUPIN) receives U.S. FDA approval for Pitolisant Tablets, marking a significant milestone in its pharmaceutical portfolio.
Lupin Limited (NSE: LUPIN) receives U.S. FDA approval for Diazepam Injection USP, expanding its therapeutic offerings.
Gland Pharma Limited (GLAND) receives USFDA approval for Sugammadex Injection 200 mg/2 mL, expanding its injectable portfolio.
Natco Pharma Limited (NSE: NATCO PHARM) receives tentative approval from U.S. FDA for Olaparib tablets, bioequivalent to Lynparza.
Lupin Limited (LUPIN) secures tentative approval from U.S. FDA for Enzalutamide Tablets, expanding dosage options.
Alembic Pharmaceuticals Limited (APLLTD) secures USFDA tentative approval for Larotrectinib Capsules, marking a significant milestone.
Natco Pharma Limited (NSE: NATCO PHARM) announces FDA approval for Eribulin Mesylate Injection, a bioequivalent to Halaven®.
Lupin Limited (LUPIN) and Natco Pharma receive FDA approval for Eribulin Mesylate Injection, a bioequivalent to Halaven®.